Professional Documents
Culture Documents
Synthesis and Molecular Docking Study of 6-Chlorop
Synthesis and Molecular Docking Study of 6-Chlorop
Synthesis and Molecular Docking Study of 6-Chlorop
Nur Pasca Aijijiyah1, Muhammad Riza Ghulam Fahmi2, Sri Fatmawati1, Mardi
Santoso1,*
1
Department of Chemistry, Faculty of Science, Institut Teknologi Sepuluh Nopember,
Kampus ITS Sukolilo Surabaya 60111, Indonesia
2
Ma Chung Research Center for Photosynthetic Pigments, Universitas Ma Chung,
Villa Puncak Tidar N-01, Malang 65151,Indonesia
Abstract. One of the most lethal and frequent infectious diseases worldwide is tuberculosis.
Multi and extensively tuberculosis drug-resistant constitutes a serious problem and emphasizes
the need for novel anti-tubercular agents. Accordingly, various pyrazine-2-carboxamides were
synthesized and evaluated as potential anti-tuberculosis agents. The synthesis involved reaction
of pyrazinoic acids with thionyl chloride to yield acyl chlorides which on treatment with various
anilines gave various pyrazine-2-carboxamides. Based on structure-activity relationships
extracted from previously published, this paper reported the synthesis and molecular docking
study of 6-chloropyrazine-2-carboxamides. Synthesis involved reaction of 6-chloropyrazinoic
acid with 2,4,6-trichlorobenzoyl chloride instead of thionyl chloride which listed under the
Chemical Weapons Convention as it may use for the production of chemical weapons. Structure
identification of 6-chloropyrazine-2-carboxamides was carried out by 1H NMR, 13C NMR, FTIR,
and high-resolution mass spectroscopy. It is predicted that 6-chloro-N-octylpyrazine-2-
carboxamide has better bioactivity against Mycobacterium tuberculosis, based on molecular
docking study.
1. Introduction
Mycobacterium tuberculosis (MTB) bacteria leads to tuberculosis disease wich primarily attacks the
lungs [1]. In 2018, the World Health Organization reported that Indonesia is a country with a high TB
burden [2]. The Ministry of Health Indonesia (2019) reported that there were 511,873 cases of TB in
2018 [3]. The genetic mutation of the TB bacteria causes resistance against first-line TB drugs called
multi-drug resistant TB. This disease becomes a more serious problem with the formation of extensively
drug-resistant TB wich bacteria MTB resistance against first-line and several second-line TB drugs [4].
Nowadays, TB treatment uses first-line drugs (isoniazid and rifampicin) and second-line drugs such as
amikacin (injectable drugs) and levoflaxin (fluoroquinolones derivatives) [5]. However, this treatment
is not enough to treat TB patients with resistance to TB drugs. [6]. The Food and Drug Administration
has assigned two kinds of antituberculosis drugs for the medication of the patient with drug-resistant
TB, namely bedaquiline (TMC207) and nitroimidazole bicyclic (PA-824), but both of them are reported
to have a side effect that causes abnormal heart rhythms and sudden cardiac death [7]. Accordingly, the
development of new antituberculosis drugs are needed.
Content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution
of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
Published under licence by IOP Publishing Ltd 1
The 2nd International Conference on Chemistry and Material Science (IC2MS) IOP Publishing
IOP Conf. Series: Materials Science and Engineering 833 (2020) 012002 doi:10.1088/1757-899X/833/1/012002
2. Experimental Section
2
The 2nd International Conference on Chemistry and Material Science (IC2MS) IOP Publishing
IOP Conf. Series: Materials Science and Engineering 833 (2020) 012002 doi:10.1088/1757-899X/833/1/012002
RCSB Protein Databank. The protein and reference ligand (NAI) were prepared using Molegro Virtual
Docking (MVD) 5.0. The preferred docking pose of each compound was performed by 50 runs of
Moldock search by the Lamarckian genetic algorithm (LGA) and the results were visualized using
MVD.
3.1. Chemistry
3
The 2nd International Conference on Chemistry and Material Science (IC2MS) IOP Publishing
IOP Conf. Series: Materials Science and Engineering 833 (2020) 012002 doi:10.1088/1757-899X/833/1/012002
Table 1. Rerank score and interaction of compound (1a-c) within the InhA
protein binding site of M. tuberculosis.
Compound Rerank score Interaction
H-Bond: Val65
(1a) -79.8858
π-π:Ile16, Ile122, Asp64, and Val65
H-Bond: Gly96
(1b) -79.1557
π-π: Gly14, Val65, Phe41, Ile95, and Gly95
H-Bond: -
(1c) -85.7435
π-π:Gly14, Phe41, Leu63, and Gly40
Figure 1. The docking pose of compound (1c) at the InHA protein binding site of M. tuberculosis.
4. Conclusion
The synthesis of 6-chloropyrazine-2-carboxylic acid derivatives (1a-c) has been successfully carried out
with the presence of TCBC. Amidation of 6-chloropyrazine-2-carboxylic acid gave compounds (1a-c)
in 71-75% yields. The molecular docking studies result revealed that 6-chloro-N-octylpyrazine-2-
carboxamide (1c) has the best activity against Mycobacterium tuberculosis H37Rv strain.
Acknowledgments
The authors are very grateful to the Indonesian Government for the PenelitianTesis Master Grant No.
796/PKS/ITS/2019.
References
[1] Garcia-monco J C 2014 Handbook of Clinical Neurology vol 121, ed J Biller and J M Ferro
(Amsterdam: Elevier BV) 1485–99
[2] World Health Organisation 2018 Global Health TB Report 2018 (Genewa: WHO)
[3] Ministry of Health Indonesia 2019 Profil Kesehatan Indonesia 2018 (Jakarta: Kemenkes RI)
[4] Bouz G, Juhás M, Niklová P, Jand’ourek O, Paterová P, Ek J J, Tůmová L, Kovalíková Z, Kastner
P, Dolezal M and Zitko J 2017 Molecules 22 1–19
[5] Unissa A N, Hanna L E and Swaminathan S 2016 Chem. Biol. Drug Des. 87 537–50
[6] Hopewell P C, Kato-maeda M and Ernst J D 2016 Murray and Nadel’s Textbook of Respiratory
Medicine vol 10, ed V C Broaddus et al (Philadelphia: Elsevier Saunders) 593–628
[7] Onajole O K, Pieroni M, Tipparaju S K, Lun S, Stec J, Chen G, Gunosewoyo H, Guo H, Ammerman
N C, Bishai W R and Kozikowski A P 2013 J. Med. Chem. 56 4093–103
[8] Ugwu D I, Ezema B E, Eze F U and Ugwuja D I 2014 Int. J. Med. Chem. 2014 1–18
[9] Njire M, Tan Y, Mugweru J, Wang C, Guo J, Yew W W, Tan S and Zhang T 2016 Adv. Med. Sci.
4
The 2nd International Conference on Chemistry and Material Science (IC2MS) IOP Publishing
IOP Conf. Series: Materials Science and Engineering 833 (2020) 012002 doi:10.1088/1757-899X/833/1/012002
61 63–71
[10] Dolezal M, Cmedlova P, Palek L, Vinsova J, Kunes J, Buchta V, Jampilek J and Kralova K 2008
Eur. J. Med. Chem. 43 1105–13
[11] Servusová B, Eibinová D, Doležal M, Kubíček V, Paterová P, Peško M and Král’ová K 2012
Molecules 17 13183–98
[12] Zitko J, Servusová B, Paterová P, Mandíková J, Kubíček V, Kučera R, Hrabcová V, Kuneš J,
Soukup O and Doležal M 2013 Molecules 18 14807–25
[13] Zitko J, Barbora S V, Paterova P, Navratilova L, Trejtnar F, Kunes J and Dolezal M 2016 Chem.
Pap.70 649–57
[14] Bouz G, Semelková L, Jand’ourek O, Konečná K, Paterová P, Navrátilová L, Kubíček V, Kuneš J,
Doležal M and Zitko J 2019 Molecules 24 1–19
[15] Sarmah K K, Rajbongshi T, Bhowmick S and Thakuria R 2017 Acta Crystallogr. Sect. B Struct.
Sci. Cryst. Eng. Mater. 73 1007–16
[16] Servusová B, Vobicková J, Paterová P, Kubíček V, Kuneš J, Doležal M and Zitko J 2013
Bioorganic Med. Chem. Lett. 23 3589–91
[17] Kostiainen O 2000 Handbook of Analytical Separations vol 2, ed M J Bogusz (Amsterdam:
Elsevier BV) 405–35
[18] Wehrstedt K D, Wandrey P A and Heitkamp D 2005 J. Hazard. Mater. 126 1–7
[19] Zhao W 2017 Handbook for Chemical Process Research Development (Boca Raton: CRC Press
Taylor & Francis Group)
[20] Ewin R A and Pertusati F 2013 Encycl. Reag. Org. Chem. 2–6
[21] Tsakos M, Schaffert E S, Clement L L, Villadsen N L and Poulsen T B 2014 Nat. Prod. Rep. 1 25
[22] Kamadatu L and Santoso M 2015 Proc. 1st Int. Seminar on Science and Technology August 5th
2015, Surabaya vol 1 pp J633-193–4
[23] Maharani N and Santoso M 2015 Adv. Environ. Biol. 9 214–8
[24] Dhimitruka I and SantaLucia J 2006 Org. Lett. 8 47–50
[25] Meng X-Y, Zhang H-X, Mezei M and Cui M 2011 NIH Public Access 7 146–57